Medtronic Stock Price, News & Analysis

Medtronic (NYSE: MDT) has announced compelling five-year outcomes from the Evolut Low Risk Trial for its Evolut™ TAVR system. The study, involving 1,414 patients (730 TAVR, 684 surgery), demonstrated that TAVR patients experienced comparable rates of all-cause mortality or disabling stroke (15.5%) versus surgery (16.4%) at five years.

Key findings showed a numerically lower rate of cardiovascular mortality in TAVR patients (7.2%) compared to surgery (9.3%), along with significantly larger effective orifice areas and lower mean gradients. The trial evaluated patients with severe aortic stenosis who had a predicted 30-day mortality risk below 3%.

The results, presented at the American College of Cardiology's Annual Scientific Session & Expo, support Evolut's supra-annular, self-expanding TAVR as a durable and effective alternative to surgery for severe aortic stenosis patients, regardless of surgical risk.

Medtronic (NYSE: MDT) has released two-year results from the SMART Trial, comparing their Evolut TAVR system with SAPIEN TAVR in patients with small aortic annulus. The study, presented at CRT 2025, is the largest international head-to-head comparative trial primarily enrolling women (87% of 716 patients) across 80+ sites worldwide.

The trial demonstrated comparable outcomes in mortality, disabling stroke, and heart failure hospitalization between both devices. However, Evolut TAVR showed superior valve performance with significantly less bioprosthetic valve dysfunction (BVD). Key findings include five times less prosthetic valve thrombosis and nine times less hemodynamic structural valve dysfunction compared to SAPIEN TAVR.

Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025. The dividend will be paid on April 11, 2025, to shareholders of record as of March 28, 2025.

This declaration aligns with the dividend increase announced in May 2024. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases.

Headquartered in Galway, Ireland, Medtronic is a global healthcare technology company with 95,000+ employees across more than 150 countries. The company develops technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.

Medtronic (NYSE:MDT) has received FDA approval for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), marking a significant advancement in Parkinson's disease treatment. The system represents the largest commercial launch of brain-computer interface technology to date.

The BrainSense™ Adaptive technology enhances Medtronic's Percept™ DBS neurostimulators by automatically adjusting therapy based on real-time brain activity, both in clinical settings and daily life. This personalized neuromodulation system has already served over 40,000 DBS patients worldwide with Percept™ devices.

The approval includes the BrainSense™ Electrode Identifier, which accelerates DBS programming settings by 85% compared to traditional methods. The technology is also available in Europe, with U.S. patient programming set to begin at select healthcare systems in the coming weeks, followed by nationwide availability in the coming months.

Medtronic (NYSE: MDT) reported Q3 FY25 financial results with revenue of $8.3 billion, up 2.5% as reported and 4.1% organic. GAAP diluted EPS was $1.01, increasing 2%, while non-GAAP diluted EPS reached $1.39, up 7%.

Key performance highlights include strong growth in Cardiac Ablation Solutions (low-20s growth) driven by pulsed field ablation products, and Diabetes revenue increasing 8.4% as reported. The company maintained its full-year guidance, expecting organic revenue growth of 4.75% to 5% and FY25 diluted non-GAAP EPS between $5.44 and $5.50.

The Cardiovascular Portfolio revenue grew 3.7% as reported, Neuroscience Portfolio increased 4.4%, while Medical Surgical Portfolio decreased 1.9%. The company highlighted significant improvements in both gross margin and operating margin, marking the ninth consecutive quarter of mid-single digit organic revenue growth.

Medtronic (NYSE: MDT) has announced it will release its third quarter fiscal year 2025 financial results on Tuesday, February 18, 2025. The earnings release will be available at 5:45 a.m. CST, followed by a video webcast at 7:00 a.m. CST to discuss the results for the quarter that ended January 24, 2025.

The company has also outlined its upcoming earnings release schedule, including Q4 FY2025 results on May 21, 2025, and quarterly results for FY2026 scheduled for August 19, 2025, November 18, 2025, February 17, 2026, and May 20, 2026.

Medtronic, headquartered in Galway, Ireland, is a global healthcare technology company with 95,000+ employees across 150+ countries. Their technologies treat 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems.

Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.

Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.

In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.

Medtronic (NYSE: MDT) has appointed Thierry Piéton as Chief Financial Officer, effective March 3, 2025. Piéton, who joins from Renault Group where he served as CFO since March 2022, will report to Chairman and CEO Geoff Martha and join the Executive Committee.

Under Piéton's leadership at Renault, the company achieved record operating margins and improved free cash flow, while executing portfolio management through acquisitions, divestitures, and innovative partnerships. His experience spans healthcare and regulated manufacturing industries, including roles at Nissan Motor, General Electric, GE Healthcare, and PricewaterhouseCoopers.

Gary Corona, who has been serving as interim CFO, will transition to Senior Vice President, Corporate Finance and remain on the Executive Committee. During Corona's interim tenure, Medtronic delivered revenue growth and exceeded EPS expectations in the first and second quarters.

Medtronic (NYSE: MDT) announced that the Centers for Medicare & Medicaid Services (CMS) is initiating a national coverage analysis (NCA) for renal denervation procedures for hypertension patients. This analysis will help develop a national Medicare coverage policy for the Symplicity™ Spyral renal denervation system, a minimally invasive treatment for high blood pressure.

The NCA was initiated in response to Medtronic's request to support Medicare beneficiary access to the system. This follows Medtronic's collaboration with CMS on the Transitional Coverage for Emerging Technologies (TCET) pathway for the FDA-approved breakthrough device. The expected completion date for the national coverage analysis is October 11, 2025. Until then, Symplicity blood pressure procedures will continue to be evaluated for coverage based on individual Medicare patient medical necessity.